Blue Cross Blue Shield · Pediatric Targeted Therapy · US health-plan appeal rights

Pediatric Targeted Therapy denied as not FDA-approved for this use by Blue Cross Blue Shield?

Q: How long do I have to appeal a Blue Cross Blue Shield Pediatric Targeted Therapy denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

Off-label use is widespread in medicine. If the literature and a recognised specialty-society guideline support the use, plans frequently approve on appeal — especially for cancer, cardiology, and rare disease.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Blue Cross Blue Shield typically requires

Blue Cross Blue Shield's specific coverage criteria for pediatric targeted therapy are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: BCBS Tumor-Agnostic Targeted Therapy (Vitrakvi / Rozlytrek / Koselugo / Ojemda)

The Blue Cross Blue Shield angle on Pediatric Targeted Therapy

## Why BCBS Denied This Claim — and Why You Can Appeal

BCBS's "not FDA-approved" denial for a pediatric targeted therapy requires careful analysis before appealing, because there are two distinct situations it may reflect: (1) the drug genuinely lacks FDA approval for the specific indication, and is being prescribed off-label; or (2) BCBS's policy has not been updated to reflect a recent FDA approval or a pediatric-specific labeling extension. In pediatric oncology, off-label use of FDA-approved agents is a recognized, guideline-supported, and standard-of-care practice — many pediatric cancers affect too few patients per year for standard pivotal trial pathways, making off-label use the clinical norm rather than the exception. Either situation is appealable.

## Your Federal Appeal Rights

Internal appeal (ERISA §503 / ACA §2719): File a written appeal within the deadline on the denial notice. If the drug is FDA-approved for any indication, the appeal should establish that the prescribed use is consistent with accepted pediatric medical practice even if off-label.
External review (ACA §2719): After final internal denial, file with an IRO within approximately four months. External reviewers must consider whether the treatment is consistent with accepted medical and scientific evidence — not merely with BCBS's internal approval list.
Expedited option: Pediatric oncology and serious pediatric illness qualify for expedited review. Request it whenever delay poses a clinical risk.

## Documentation to Gather

1. FDA label and approval history — print the current prescribing information. If the drug is approved for an adult indication and used off-label in a pediatric patient, note this explicitly and address it in the appeal. 2. Pediatric guideline organization support — the prescriber's letter should cite the relevant guideline organization (e.g., COG, NCCN Pediatric, relevant subspecialty society) and explain that off-label use in this context reflects standard pediatric practice. 3. Published peer-reviewed literature — attach studies or consensus statements supporting the use of this agent in this pediatric indication. 4. Institutional support — a letter from the treating children's hospital, tumor board, or subspecialty committee supporting the treatment plan adds significant weight. 5. Diagnosis and biomarker documentation — confirms the clinical basis for the treatment selection. 6. Prescriber's medical-necessity letter — ties all of the above together in a clinically coherent narrative.

## Criteria-Mapping Structure for Your Appeal Letter

| BCBS not-FDA-approved basis | Your response | |---|---| | Drug not approved for this indication | FDA label (any approval) + off-label standard-of-care evidence | | Pediatric use not separately approved | Published guideline org support + institutional letter | | BCBS policy excludes off-label use | Plan language review + argument that exclusion is overbroad for pediatric context |

Many BCBS plan documents contain an exception to their off-label exclusion for oncology use — review your Summary Plan Description and Evidence of Coverage for this language, and cite it in your appeal if present.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Blue Cross Blue Shield appeals

Other denial reasons for Blue Cross Blue Shield Pediatric Targeted Therapy

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.